Quentin Durand


Quentin Durand


Paris | 32 rue de Monceau, Paris, France 75008
+33 1 57 57 80 05 | +33 1 57 57 80 81

| vCard | PDF

Quentin Durand focuses his practice on corporate and securities matters with an emphasis on capital markets, including public company reporting and governance issues.

Mr. Durand has significant experience representing companies and shareholders in public equity offerings as well as in public takeovers. He has been involved in various M&A and ECM transactions both domestic and cross border as well as in private equity transactions in growth and venture capital across a wide range of industry sectors, including healthcare, technology and financial services.

Prior to joining Dechert, Mr. Durand served as a legal officer within the corporate finance and the supervision of enforcement divisions of the Autorité des marchés financiers where he was involved in numerous transactions (more than 20 IPOs and numerous secondary offerings) and regulatory work. He also acted as a prosecutor before the AMF enforcement committee.


Capital Markets / Public M&A

  • MedinCell in the context of its IPO on the regulated market Euronext in Paris. 
  • Abivax in Kreos Capital Financing. 
  • Bryan Garnier & Co Ltd and RBC Europe Limited with the public offering of Biom’Up.
  • Vexim, a French medtech company, in connection with the €183m tender offer from Stryker Corporation.
  • Bryan Garnier & Co Ltd and RBC Europe Limited, as financial intermediaries in the context of Biom'Up's IPO on compartment C of the Euronext regulated market in Paris.
  • Medtech, a medical robotic company, in the $175 million tender offer from Zimmer Biomet, as well as in a $25 million cross-over financing with Ally Bridge Group (HK).
  • Poxel, a biopharmaceutical company, in two cross-over financing (PIPEs) from various international investors for an aggregate amount of $46.5 million, as well as on various corporate governance issues.
  • Underwriters led by Citigroup Global Markets Inc. and Jefferies LLC in the $75 million U.S. initial public offering of Advanced Accelerator Applications S.A. a pharmaceutical company, on Nasdaq and its $172.5 million follow-on offering led by JP Morgan Securities, Jefferies LLC and Wells Fargo Securities LLC.
  • Avanquest, a software company, in a €35 million equity issue as well as various corporate governance issues.
  • Sensorion, a biopharmaceutical company, on a $8 million cross-over financing with a U.S. investor.
  • Extendam, an asset management company, on an equity public offering.

Private Equity / M&A

  • Clearwater, an independent corporate finance boutique, in the acquisition of a minority stake of its share capital by Credit Mutuel Arkea.
  • Equitis, a trust management company, in its acquisition by Astorg.
  • Comgest Global Investors, a financial services company, in the acquisition of a Luxembourg based target.
  • Sofibus, a real estate company, in the reorganization of its shareholdings structure.
  • Venture capital funds led by Sofinnova Partners, BPI InnoBio and Morningside Ventures on their investment in Enyo, a biopharmaceutical Company.
  • AID, a big data company, in a venture capital investment of Midi Capital.
  • ESCP Europe, Master in Management Grande Ecole, 2008
  • University of Potsdam, Germany, B.A., German-French Law, 2004
  • Université Paris-Sud XI, Master 2, Business Law, 2008
  • EFB, Certificat d'Aptitude à la Profession d'Avocat, 2010
  • Paris
  • French
  • English
  • German